Status: Recruiting
Use of Long-Acting Injectable Cabotegravir/Rilpivirine for the Treatment of HIV in Belgium
This will be a multi-center, single arm observational cohort study with an assessment of patient-reported outcomes (PROs) and of clinical and virologic outcomes. Primary outcome • Evaluate patient perception of, and satisfaction with, long-acting injectable (LAI) cabotegravir/rilpivirine (CAB/RPV) for the treatment of HIV Secondary outcomes • Description of the demographic, HIV-, and non-HIV-related characteristics of participants included in this analysis
Participants needed: 600
Trial details
Age: 18-99Biological sex: AllType: ObservationalSponsor: Belgian Research on AIDS and HIV ConsortiumUpdated: Feb 5, 2025Locations: 1
Eligibility criteria
HIV-1 patients, aged 18 years and above, having received at least 1 dose of LAI...